Exploring Cefiderocol Resistance Mechanisms in Burkholderia pseudomallei.

Anti-Bacterial Agents / pharmacology Burkholderia pseudomallei Gram-Negative Bacteria Cephalosporins / pharmacology Drug Resistance, Multiple, Bacterial / genetics Microbial Sensitivity Tests Cefiderocol
Burkholderia pseudomallei cefiderocol resistance

Journal

Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061

Informations de publication

Date de publication:
15 06 2023
Historique:
medline: 19 6 2023
pubmed: 3 5 2023
entrez: 3 5 2023
Statut: ppublish

Résumé

Cefiderocol is a siderophore cephalosporin designed mainly for treatment of infections caused by β-lactam and multidrug-resistant Gram-negative bacteria. Burkholderia pseudomallei clinical isolates are usually highly cefiderocol susceptible, with

Identifiants

DOI: 10.1128/aac.00171-23 PMID: 37133377 PMC: PMC10269091
pubmed: 37133377
doi: 10.1128/aac.00171-23
pmc: PMC10269091
doi:

Substances chimiques

Anti-Bacterial Agents 0
Cephalosporins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0017123

Déclaration de conflit d'intérêts

The authors declare no conflict of interest.

Références

Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S529-S537
pubmed: 31724044
Open Forum Infect Dis. 2021 Jun 12;8(7):ofab311
pubmed: 34262990
Microb Drug Resist. 2022 Apr;28(4):398-407
pubmed: 35076335
Bioinformatics. 2008 Dec 1;24(23):2803-4
pubmed: 18842600
PLoS One. 2012;7(2):e30789
pubmed: 22363490
mBio. 2013 Jul 16;4(4):
pubmed: 23860767
Expert Rev Anti Infect Ther. 2019 May;17(5):307-309
pubmed: 31055983
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S538-S543
pubmed: 31724047
Int J Antimicrob Agents. 2014 Apr;43(4):310-8
pubmed: 24613038
Nature. 2000 Aug 31;406(6799):959-64
pubmed: 10984043
PLoS Pathog. 2020 Mar 5;16(3):e1008298
pubmed: 32134991
J Glob Antimicrob Resist. 2022 Mar;28:120-124
pubmed: 34958997
mBio. 2020 Apr 14;11(2):
pubmed: 32291300
Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17165-70
pubmed: 21969582
Antimicrob Agents Chemother. 2020 Oct 20;64(11):
pubmed: 32868330
Antibiotics (Basel). 2022 May 27;11(6):
pubmed: 35740130
Antimicrob Agents Chemother. 2014;58(1):162-6
pubmed: 24145517
Int J Antimicrob Agents. 2023 Mar;61(3):106714
pubmed: 36640845
Clin Infect Dis. 2021 Dec 6;73(11):e4472-e4474
pubmed: 33411899
Diagn Microbiol Infect Dis. 2017 Jun;88(2):198-200
pubmed: 28410852
Nucleic Acids Res. 2019 Jul 2;47(W1):W636-W641
pubmed: 30976793
Antimicrob Agents Chemother. 2003 Jul;47(7):2082-7
pubmed: 12821450
Antimicrob Agents Chemother. 2021 Jan 20;65(2):
pubmed: 33168603
Infect Drug Resist. 2012;5:129-32
pubmed: 22977307
Infect Immun. 2010 Jul;78(7):3136-43
pubmed: 20404077
Antimicrob Agents Chemother. 1999 Mar;43(3):465-70
pubmed: 10049252
Sci Rep. 2018 Jul 13;8(1):10652
pubmed: 30006637
Nat Rev Dis Primers. 2018 Feb 01;4:17107
pubmed: 29388572
PLoS Negl Trop Dis. 2012;6(6):e1715
pubmed: 22745846
J Glob Antimicrob Resist. 2020 Sep;22:738-741
pubmed: 32702396
Antimicrob Agents Chemother. 2018 May 25;62(6):
pubmed: 29555629
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29061741

Auteurs

Carina M Hall (CM)

The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.

Nawarat Somprasong (N)

The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.

Johannah P Hagen (JP)

The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.

Roxanne Nottingham (R)

The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.

Jason W Sahl (JW)

The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
Department of Biological Sciences, Northern Arizona University, Flagstaff, Arizona, USA.
ORCID: 0000-0002-2497-0138

Jessica R Webb (JR)

Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.
Department of Microbiology and Immunology at the Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, Australia.

Mark Mayo (M)

Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.

Bart J Currie (BJ)

Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia.

Yuwana Podin (Y)

Institute of Health and Community Medicine, Universiti Malaysia Sarawak, Sarawak, Malaysia.

David M Wagner (DM)

The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
Department of Biological Sciences, Northern Arizona University, Flagstaff, Arizona, USA.

Paul Keim (P)

The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
Department of Biological Sciences, Northern Arizona University, Flagstaff, Arizona, USA.
ORCID: 0000-0003-0089-5820

Herbert P Schweizer (HP)

The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.
Department of Biological Sciences, Northern Arizona University, Flagstaff, Arizona, USA.
ORCID: 0000-0002-8847-335X

Articles similaires

Vancomycin-associated DRESS demonstrates delay in AST abnormalities.

Ahmed Hussein, Kateri L Schoettinger, Jourdan Hydol-Smith et al.
1.00
Humans Drug Hypersensitivity Syndrome Vancomycin Female Male

Management of the infected total elbow arthroplasty.

Joaquin Sanchez-Sotelo
1.00
Humans Arthroplasty, Replacement, Elbow Prosthesis-Related Infections Debridement Anti-Bacterial Agents

Mathematical modeling of vancomycin release from Poly-L-Lactic Acid-Coated implants.

Papon Thamvasupong, Kwanchanok Viravaidya-Pasuwat
1.00
Vancomycin Polyesters Anti-Bacterial Agents Models, Theoretical Drug Liberation

Menthol as an effective inhibitor of quorum sensing and biofilm formation in Candida albicans and Candida glabrata by targeting the transcriptional repressor TUP1.

Pouria Khodavandi, Maryam Miri Soogh, Fahimeh Alizadeh et al.
1.00
Biofilms Candida albicans Quorum Sensing Candida glabrata Menthol

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-infectieux › Antibactériens › Exploring Cefiderocol Resistance Mechanisms in...
questionsmedicales.fr › Bactéries › Proteobacteria › Betaproteobacteria › Burkholderiales › Burkholderiaceae › Burkholderia › Burkholderia pseudomallei › Exploring Cefiderocol Resistance Mechanisms in...
questionsmedicales.fr › Bactéries › Bactéries à Gram négatif › Exploring Cefiderocol Resistance Mechanisms in...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › bêta-Lactames › Céphalosporines › Exploring Cefiderocol Resistance Mechanisms in...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Multirésistance aux médicaments › Multirésistance bactérienne aux médicaments › Exploring Cefiderocol Resistance Mechanisms in...
questionsmedicales.fr › Techniques d'investigation › Évaluation préclinique de médicament › Tests de sensibilité microbienne › Exploring Cefiderocol Resistance Mechanisms in...